Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
Article
PubMed
Google Scholar
Campbell SC, Lane, BR. Malignant Renal Tumors. In: Campbell-Walsh Urology, 10th Edition. 10th edn. Edited by Kavoussi L, Novick A, Partin A, Peters C; 2012: 1443–1444.
Vaishampayan U, Vankayala H, Vigneau FD, Quarshie W, Dickow B, Chalasani S, et al. The Effect of Targeted Therapy on Overall Survival in Advanced Renal Cancer: A Study of the National Surveillance Epidemiology and End Results Registry Database. Clin Genitourin Canc. 2014;12(2):124–9.
Article
Google Scholar
Haas NB, Uzzo RG. Targeted therapies for kidney cancer in urologic practice. Urol Oncol-Semin Ori. 2007;25(5):420–32.
Article
Google Scholar
Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277(5322):55–60.
Article
CAS
PubMed
Google Scholar
Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell AI, Master Z, Bendeck MP, et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res. 2001;49(3):659–70.
Article
CAS
PubMed
Google Scholar
Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer. 2010;10(8):575–85.
Article
CAS
PubMed
Google Scholar
Kucejova B, Sunny NE, Nguyen AD, Hallac R, Fu X, Pena-Llopis S, et al. Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death. Oncogene. 2011;30(18):2147–60.
Article
CAS
PubMed
PubMed Central
Google Scholar
Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452(7184):230–3.
Article
CAS
PubMed
Google Scholar
Wechsel HW, Petri E, Bichler KH, Feil G. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res. 1999;19(4A):2583–90.
CAS
PubMed
Google Scholar
Nisman B, Yutkin V, Nechushtan H, Gofrit ON, Peretz T, Gronowitz S, et al. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy. Urology. 2010;76(2):513. e511-516.
Article
PubMed
Google Scholar
Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010;183(1):68–75.
Article
PubMed
Google Scholar
Hernandez-Yanez M, Heymach JV, Zurita AJ. Circulating biomarkers in advanced renal cell carcinoma: clinical applications. Curr Oncol Rep. 2012;14(3):221–9.
Article
CAS
PubMed
Google Scholar
Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer. 1998;77(6):956–64.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res. 2010;16(11):3044–56.
Article
CAS
PubMed
Google Scholar
Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009;10(3):165–77.
Article
CAS
PubMed
Google Scholar
Ahmad SA, Liu W, Jung YD, Fan F, Wilson M, Reinmuth N, et al. The effects of angiopoietin-1 and −2 on tumor growth and angiogenesis in human colon cancer. Cancer Res. 2001;61(4):1255–9.
CAS
PubMed
Google Scholar
Sallinen H, Heikura T, Laidinen S, Kosma VM, Heinonen S, Yla-Herttuala S, et al. Preoperative angiopoietin-2 serum levels: a marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(9):1498–505.
PubMed
Google Scholar
Bhaskar A, Gupta R, Vishnubhatla S, Kumar L, Sharma A, Sharma MC, et al. Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma. Luek Lymphoma. 2013;54(7):1473–8.
Article
CAS
Google Scholar
Srirajaskanthan R, Dancey G, Hackshaw A, Luong T, Caplin ME, Meyer T. Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis. Endocr Relat Cancer. 2009;16(3):967–76.
Article
CAS
PubMed
Google Scholar
Currie MJ, Gunningham SP, Turner K, Han C, Scott PA, Robinson BA, et al. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J Pathol. 2002;198(4):502–10.
Article
CAS
PubMed
Google Scholar
Bullock AJ, Zhang L, O’Neill AM, Percy A, Sukhatme V, Mier JW, et al. Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC). [Abstract] J Clin Oncol. 2010;28:15s. suppl; abstr 4630.
Google Scholar
Pal SK, Williams S, Josephson DY, Carmichael C, Vogelzang NJ, Quinn DI. Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Ther. 2012;11(3):526–37.
Article
CAS
PubMed
PubMed Central
Google Scholar
Landt S, Jeschke S, Koeninger A, Thomas A, Heusner T, Korlach S, et al. Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancer. Anticancer Res. 2010;30(2):375–81.
CAS
PubMed
Google Scholar
Hathurusinghe HR, Goonetilleke KS, Siriwardena AK. Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy. Ann Surg Oncol. 2007;14(10):2714–20.
Article
PubMed
Google Scholar
Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loening SA. Tumor M2 pyruvate kinase in plasma of patients with urological tumors. Tumour Biol. 2001;22(5):282–5.
Article
CAS
PubMed
Google Scholar
Varga Z, Hegele A, Stief T, Heidenreich A, Hofmann R. Determination of pyruvate kinase type tumor M2 in human renal cell carcinoma: a suitable tumor marker? Urol Res. 2002;30(2):122–5.
Article
CAS
PubMed
Google Scholar
Singer EA, Gupta GN, Marchalik D, Srinivasan R. Evolving therapeutic targets in renal cell carcinoma. Curr Opin Oncol. 2013;25(3):273–80.
CAS
PubMed
Google Scholar
Parker AS, Leibovich BC, Lohse CM, Sheinin Y, Kuntz SM, Eckel-Passow JE, et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer. 2009;115(10):2092–103.
Article
PubMed
PubMed Central
Google Scholar